STUART A RANDLE
CIK 1256144 · Interim President and CEO · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.26M
Companies
4
Total Filings
86
Lifetime Open-Market Net
-$9.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TFX | Interim President and CEO | 16,524 | $136.71 | $2.26M | -$6.63M | 36 | 2026-06-09 |
| QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Director | 0 | $124.17 | $0 | -$3.33M | 35 | 2025-04-29 |
| Comera Life Sciences Holdings, Inc. (CMRAW) Delisted | Director | 74,116 | $0.02 | $1.4K | $41.6K | 5 | 2023-09-01 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | — | — | — | $0 | 4 | 2018-07-26 |
Recent Filings · Page 5 of 9
86 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-09 | TFX | Mixed | — | -$556.2K | EDGAR |
| 2018-07-26 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-18 | TFX | Grant (A) | +389 | $0 | EDGAR |
| 2018-02-15 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-02-13 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Exer (M) | +1,987 | $0 | EDGAR |
| 2017-07-27 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-08 | TFX | Mixed | — | -$407.3K | EDGAR |
| 2017-05-10 | TFX | Grant (A) | +440 | $0 | EDGAR |
| 2017-02-14 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-13 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Exer (M) | +2,657 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.